Mandate

Vinge advises Expedition Growth Capital in connection with Storykit’s USD 10 million investment round

Vinge advises Expedition Growth Capital in connection with Storykit’s investment round of USD 10 million led by Expedition Growth Capital. The investment in Storykit is Expedition Growth Capital’s first investment in the Nordics.

Serving large and medium sized enterprises, Storykit is leveraging artificial intelligence enabling its users to create video and tell stories on social platforms, and has quickly grown to become the leading video creator in the Nordics as well as recently expanded into several European markets. With the new funding, they will accelerate innovation and expansion at an even higher pace.

Expedition Growth Capital is a USD 200+ million London-based growth equity fund, focused solely on investing in fast growing and capital efficient B2B software companies in Europe and Israel, and this is Expedition Growth Capital’s first investment in the Nordics.

Vinge’s team consisted of Karl Klackenberg, Johan Larsson, Milad Kamali and Nina Gransäter (M&A), Stojan Arnerstål (IPR), Lisa Hörnqvist (Commercial Agreements) and Veronika Garemark (Employment).

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025